Author:
Setola Elisabetta,Benini S.,Righi A.,Gamberi G.,Carretta E.,Ferrari C.,Avnet S.,Palmerini E.,Magagnoli G.,Gambarotti M.,Lollini P. L.,Cesari M.,Cocchi S.,Paioli A.,Longhi A.,Scotlandi K.,Laginestra M. A.,Donati D. M.,Baldini N.,Ibrahim T.
Abstract
Abstract
Background
Heterozygous isocitrate dehydrogenase (IDH) mutations occur in about half of conventional central bone chondrosarcomas (CCBC). Aim of this study was to assess the frequency and prognostic impact of IDH mutations in high grade CCBC patients.
Methods
64 patients with G2 and G3 CCBC were included. DNA extraction, PCR amplification of IDH1/2 exon 4s, and sequencing analysis with Sanger were performed.
Results
IDH mutations were detected in 24/54 patients (44%): IDH1 in 18, IDH2 in 4, and both IDH1/2 in 2 patients. The frequency of mutations was 37% in G2 vs. 69% in G3 (p = 0.039), and 100% in three Ollier disease associated chondrosarcoma. 5-year overall survival (OS) at 124 months (range 1-166) was 51%, with no significant difference based on the IDH mutational status: 61% in IDHmut vs. 44% in IDH wild type (IDHwt). The 5-year relapse free survival (RFS) was 33% (95% CI:10–57) for IDHmut vs. 57% (95%CI: 30–77) for IDHwt. Progression free survival (PFS) was 25% (95%CI:1–65) IDHmut vs. 16% (95%CI: 0.7–52) IDHwt. 55% (5/9) of IDHmut G2 became higher grade at the recurrence, as compared with 25% (3/12) of G2 IDHwt.
Conclusions
This study shows a higher frequency of IDH mutations in G3 CCBC as compared with G2. No significant differences in OS, RFS, and PFS by mutational status were detected. After relapse, a higher rate of G3 for IDH mutated CCBC was observed.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference43 articles.
1. Zając AE, Kopeć S, Szostakowski B, Spałek MJ, Fiedorowicz M, Bylina E, Filipowicz P, Szumera-Ciećkiewicz A, Tysarowski A, Czarnecka AM, Rutkowski P. Chondrosarcoma-from Molecular Pathology to Novel Therapies. Cancers (Basel). 2021;13(10):2390. https://doi.org/10.3390/cancers13102390. PMID: 34069269; PMCID: PMC8155983.
2. WHO Classification of Tumours 5th Edition.: Soft Tissue and Bone Tumours. Edited by the WHO Classification of Tumours Editorial Board. IARC press: Lyon, France 2020; Vol 5.
3. Pansuriya TC, Kroon HM, Bovée JV. Enchondromatosis: insights on the different subtypes. Int J Clin Exp Pathol. 2010;3(6):557–69. PMID: 20661403; PMCID: PMC2907117.
4. Staals E, Cancer, Donati D, Bianchi G “Diagnosis of Musculoskeletal Tumors and Tumor-like Conditions” Chap. 34, pp.157–180;, Inwards CY, Bloem JL. Hogendoorn. Dedifferentiated Chondrosarcoma, WHO 2021, pp. 3388 – 390.
5. 18Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, Pollock R, O’Donnell P, Grigoriadis A, Diss T, Eskandarpour M, Presneau N, Hogendoorn PC, Futreal A, Tirabosco R, Flanagan AM. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011;224(3):334–43. https://doi.org/10.1002/path.2913. Epub 2011 May 19. PMID: 21598255.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献